

**EQUIMAX- ivermectin and praziquantel paste**  
**Bimeda Inc**

-----

**Equimax<sup>®</sup>**  
**(ivermectin 1.87 % / praziquantel 14.03 %)**  
**Paste**  
**Anthelmintic and Boticide**

FOR ORAL USE IN HORSES ONLY

Removes worms and bots with a single dose.

Contents will treat up to 1320 lb body weight.

**Net Weight: 0.225 oz (6.42 g)**

**INDICATIONS**

Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism. Equimax (ivermectin/praziquantel) Paste is indicated for the treatment and control of the following parasites:

**Tapeworms**

*Anoplocephala perfoliata*

**Large Strongyles (adults)**

*Strongylus vulgaris* (also early forms in blood vessels)

*S. edentatus* (also tissue stages)

*S. equinus*

*Triodontophorus* spp.

**Small Strongyles (adults, including those resistant to some benzimidazole class compounds)**

*Cyathostomum* spp.

*Cylicocyclus* spp.

*Cylicostephanus* spp.

*Cylicodontophorus* spp.

**Small Strongyles (fourth-stage larvae)**

**Pinworms (adults and fourth-stage larvae)**

*Oxyuris equi*

**Ascarids (adults and third- and fourth-stage larvae)**

*Parascaris equorum*

**Hairworms (adults)**

*Trichostrongylus axei*

**Large-mouth Stomach Worms (adults)**

*Habronema muscae*

**Bots (oral and gastric stages)**

*Gasterophilus* spp.

**Lungworms (adults and fourth-stage larvae)**

*Dictyocaulus arnfieldi*

**Intestinal Threadworms (adults)**

*Strongyloides westeri*

**Summer Sores** caused by *Habronema* and *Draschia* spp. cutaneous third-stage larvae

**Dermatitis** caused by **Neck Threadworm** microfilariae, *Onchocerca* sp.

## DOSAGE AND ADMINISTRATION

This syringe contains sufficient paste to treat one 1320-lb horse at the recommended dose rate of 91 mcg ivermectin per lb (200 mcg/kg) and 0.68 mg praziquantel per lb (1.5 mg/kg) of body weight. Each weight marking on the syringe plunger delivers enough paste to treat 220 lb (100 kg) of body weight.

1. While holding plunger, turn the knurled ring on the plunger 1/4 turn to the left and slide it so the side nearest the barrel is at the prescribed weight marking.
2. Lock the ring in place by making a 1/4 turn to the right.
3. Make sure that the horse's mouth contains no feed.
4. Remove the cover from the tip of the syringe.
5. Insert the syringe tip into the horse's mouth at the space between the teeth.
6. Depress the plunger as far as it will go, depositing paste on the back of the tongue.
7. Immediately raise the horse's head for a few seconds after dosing.

## Parasite Control Program

All horses should be included in a regular parasite control program with particular attention being paid to mares, foals, and yearlings. Foals should be treated initially at 4 weeks of age, and routine treatment repeated as appropriate. Consult your veterinarian for a control program to meet your specific needs. Equimax Paste effectively controls gastrointestinal nematodes, cestodes and bots of horses. Regular treatment will reduce the chances of colic caused by *Anoplocephala perfoliata* and verminous arteritis caused by *Strongylus vulgaris*.

## Product Advantages

### Broad-spectrum Control

Equimax Paste kills important internal parasites, including tapeworms, bots and the arterial stages of *S. vulgaris*, with a single dose. Equimax Paste contains two potent antiparasitic agents that are neither benzimidazoles nor organophosphates.

## SAFETY

EQUIMAX Paste may be used in horses 4 weeks of age and older. Stallions and breeding, pregnant or lactating mares may be treated without adverse effects on fertility.

In a tolerance study in which 3- to 4-week-old foals were treated at 10X once, loose watery stools were observed on post-treatment days 1, 2, and 5-9 in one foal. These signs resolved without treatment by day 10, and no other foals were affected.

In a reproductive safety study, eleven mares were treated with a 3X dose of EQUIMAX Paste every two weeks throughout breeding, pregnancy and lactation, up until the foal was three months of age. Ten mares served as controls and were treated with the vehicle paste in a similar manner. An increased incidence of colic was observed in treated mares as compared to control mares. In addition, elevations of GGT and AST were more frequent in the 3X treated mares, and in two mares these enzymes were elevated at the time of colic episodes.

One treated mare was dropped from the study because she did not conceive after three breeding attempts.

Two treated mares had abnormally short diestrous periods of two days and eight days on the first estrous cycle following the birth of the study foal. In addition, one of these two mares failed to ovulate in the second and third estrous cycles.

In the first few weeks of life, foals born to the 3X treated mares had a higher incidence of transient ocular discharge and gastrointestinal disturbances (loose stools, diarrhea) and depression requiring medical intervention as compared to foals born to control mares.

## **PRECAUTIONS**

Equimax Paste has been formulated specifically for use in horses and ponies **only**. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result.

## **WARNING**

Do not use in horses intended for human consumption.

## **HUMAN WARNINGS**

Not for use in humans. Keep this and all drugs out of the reach of children. Refrain from eating or smoking when handling. Wash hands after use. Avoid contact with eyes. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information. To report adverse reactions in users, to obtain more information, or to obtain a MSDS, contact Bimeda Inc. at 1-888-524-6332.

## **ENVIRONMENTAL WARNINGS**

Ivermectin and excreted ivermectin residues may adversely affect aquatic organisms. Do not contaminate ground or surface water. Dispose of the syringe in an approved landfill or by incineration.

Store at room temperature (25°C/77°F), with excursions permitted between 15°–30°C (59°–86°F).

## **NOTE TO USER**

Swelling and itching reactions after treatment with ivermectin paste have occurred in horses carrying heavy infections of neck threadworm (*Onchocerca* sp. *microfilariae*). These reactions were most likely the result of microfilariae dying in large numbers. Symptomatic treatment may be advisable. Consult your veterinarian should any such reactions occur. Healing of summer sores involving extensive tissue changes may require other appropriate therapy in conjunction with treatment with Equimax Paste. Reinfection, and measures for its prevention, should also be considered. Consult your veterinarian if the condition does not improve.

To report adverse reactions, call Bimeda Inc. at 1-888-524-6332.

NADA #141-215, Approved by FDA

### **Manufactured by:**

Virbac AH Inc.  
3200 Meacham Blvd  
Fort Worth, Texas 76137  
U.S. Patent No. 5,824,653

### **Distributed by:**

Bimeda, Inc.  
Le Sueur, MN 56058

Made in USA

Equimax is a Registered Trademark of Virbac SA.

October 2009

## EQUIMAX®

(ivermectin 1.87%/  
praziquantel 14.03%)

## Anthelmintic and Boticide

For the treatment and control of roundworms (ascarids, strongyles and lungworms), tapeworms, and bots in horses with a single dose.

Contents will treat up to 1320 lb body weight.

FOR ORAL USE IN HORSES ONLY

**Net Weight: 0.225 oz (6.42 g)**

NADA #141-215, Approved by FDA

## Bimeda



# EQUIMAX

ivermectin and praziquantel paste

## Product Information

<b>Product Type</b>	OTC ANIMAL DRUG	<b>Item Code (Source)</b>	NDC:6 1133-7000
<b>Route of Administration</b>	ORAL	<b>DEA Schedule</b>	

## Active Ingredient/Active Moiety

<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>
<b>ivermectin</b> (UNII: 8883YP2R6D) (ivermectin - UNII:8883YP2R6D)	ivermectin	200 ug
<b>praziquantel</b> (UNII: 6490C9U457) (praziquantel - UNII:6490C9U457)	praziquantel	1.5 mg

## Product Characteristics

<b>Color</b>	WHITE	<b>Score</b>	
<b>Shape</b>		<b>Size</b>	
<b>Flavor</b>	APPLE	<b>Imprint Code</b>	
<b>Contains</b>			

## Packaging

#	<b>Item Code</b>	<b>Package Description</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
1	NDC:6 1133-7000-1	1 in 1 CARTON		

## Marketing Information

<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
NADA	NADA141215	01/14/2010	

**Labeler** - Bimeda Inc (043653216)

**Registrant** - Virbac AH Inc (131568396)

## Establishment

<b>Name</b>	<b>Address</b>	<b>ID/FEI</b>	<b>Business Operations</b>
Virbac Bridgeton		808558100	MANUFACTURE

Revised: 1/2010

Bimeda Inc